|
gptkbp:instanceOf
|
gptkb:drug
antineoplastic agent
|
|
gptkbp:affiliatedWith
|
gptkb:milbemycin
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
P02CX08
|
|
gptkbp:CASNumber
|
113507-06-5
|
|
gptkbp:chemicalFormula
|
C37H53NO8
|
|
gptkbp:developedBy
|
gptkb:Wyeth
|
|
gptkbp:eliminationHalfLife
|
20-43 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
moxidectin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
glutamate-gated chloride channel agonist
|
|
gptkbp:molecularWeight
|
639.8 g/mol
|
|
gptkbp:origin
|
derived from Streptomyces cyanogriseus
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:relatedTo
|
gptkb:ivermectin
|
|
gptkbp:routeOfAdministration
|
oral
topical
subcutaneous injection
|
|
gptkbp:sideEffect
|
fever
abdominal pain
headache
muscle pain
itching
|
|
gptkbp:usedFor
|
treatment of onchocerciasis
treatment of river blindness
treatment of parasitic infections in animals
|
|
gptkbp:usedIn
|
gptkb:veterinary_medicine
human medicine
|
|
gptkbp:bfsParent
|
gptkb:Bayer_Advocate_(pet_product)
|
|
gptkbp:bfsLayer
|
6
|